Revolution has created “a cottage industry of competitors,” says CEO Mark Goldsmith. His answer: stay ahead on science. And what does he say about who is watching?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
1
6
“We’ve decided we will unlock any compelling strategy in first line,” says Revolution’s CEO. RASolute 303 and 304 are evaluating Rasonque in first-line PDAC. What else is in the first-line programs?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
1
13
Revolution CEO Mark Goldsmith on Rasonque’s early sales: “The uncertainty is actually baked into the data.” Three overlapping patient groups have been treated so far. Which does he expect to be the stable core of demand?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
1
8
Rasonque booked $197.6m in roughly five weeks to Sept. 30 after its Aug. 26 FDA approval, the best launch-quarter sales for an oncology drug ever. Revolution’s CEO is still tempering expectations. Why?
Therapeutic Thursday. Read it here...
capsul.news/therapeutic-thur…
The EU offers three routes for herbal medicines. The US has no herbal-specific route. Birch triterpene gel is the one product taken through both systems. How did it fare?
Watchdog Wednesday. Read it here...
capsul.news/watchdog-wednesd…
1
7
A bill would have shielded qualifying botanical drugs from generics for 12 years. Both of its sponsors were swept out of Congress by the midterms. That leaves the executive branch.
Watchdog Wednesday. Read it here...
capsul.news/watchdog-wednesd…
1
5
Sign up for Capsul here: capsul.news/join-capsul/
1
The first of the four FDA-approved botanicals, green tea extract Veregen, cleared in 2006. It has since been sponsored or marketed by six different companies. Approval is only part of the story.
Watchdog Wednesday. Read it here...
capsul.news/watchdog-wednesd…
1
6
Sign up for Capsul here: capsul.news/join-capsul/
3
Four botanical drug approvals in 26 years. The FDA has been formally encouraging submissions for more than a quarter century. So what are sponsors asking for now?
Watchdog Wednesday. Read it here... capsul.news/watchdog-wednesd…
1
10
Sign up for Capsul here: capsul.news/join-capsul/
4
Regeneron’s CIDEBsiRNA reduced liver fat by up to 80% at 36 weeks after a single dose. GSK is moving efimosfermin into four Phase III trials. All three presented MASH data at AASLD 2026. What’s the case each is making?
Trial Tuesday. Read it here...
capsul.news/trial-tuesday-st…
1
31
Sign up for Capsul here: capsul.news/join-capsul/
5
Olpasiran and lepodisiran lowered Lp(a) by more than 90% in Phase II. Leerink cut olpasiran’s probability of success from 50% to 20%. The NEJM authors argue outcomes could still differ. Who’s right?
Trial Tuesday. Read it here...
capsul.news/trial-tuesday-st…
1
13
Sign up for Capsul here: capsul.news/join-capsul/
2


